Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-Week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhea

NCT02107196 is registered in ClinicalTrials.gov with Menarini Group as lead sponsor.

NCT NCT02107196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02107196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Double-blind, Randomised, Placebo-controlled, Parallel Group Phase III Study, Followed by a 4-Week Randomised Withdrawal Period to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhea
Lead sponsor
Menarini Group
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2014
Completion date
June 30, 2015
Enrollment
535 (actual)
Sites
127

Conditions

As the registry lists them; a condition with its own page is linked.

irritable bowel syndrome with diarrhea